Menu

Image of the Day: Hungry Hookworms

Researchers discover anti-malarials called quinolones can halt the development of the parasites, offering a potential therapeutic avenue.

Mar 26, 2018
The Scientist Staff, The Scientist Staff

Adult hookworm (Nippostrongylus brasiliensis) with digested blood cells labeled with fluorescent marker PKH26T. BOUCHERY ET AL.

Researchers reported in PLOS Pathogens last week (March 22) that they have identified a pathway in hookworms (Nippostrongylus brasiliensis) involved in blood digestion that can be blocked by drugs in the quinolone family. Treating mice infected with hookworms reduced the parasites’ development and their ability to reproduce.

Tiffany Bouchery, a parasitologist at Malaghan Institute of Medical Research in New Zealand, and colleagues targeted an enzyme, aspartic protease-1 (APR-1), involved in the hookworms’ ability to break down a blood molecule called heme into digestible components. They tested the effects of quinolones, which break up similar compounds in malaria parasites, on the hookworms. The drugs disrupted the production of APR-1, and mice treated with them had lower levels of infection than controls.

T. Bouchery et al., “A novel blood-feeding detoxification pathway in Nippostrongylus brasiliensis L3 reveals a potential checkpoint for arresting hookworm development,” PLOS Pathogens, doi:10.1371/journal.ppat.1006931, 2018.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.